alexa Murine Insulinoma Cell-Conditioned Medium with ΒETA2/Neurod1 Transduction Efficiently Induces the Differentiation of Adipose-Derived Mesenchymal Stem Cells into β-Like Cells both In Vitro and In Vivo
ISSN: 2157-7633
Journal of Stem Cell Research & Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Murine Insulinoma Cell-Conditioned Medium with ΒETA2/Neurod1 Transduction Efficiently Induces the Differentiation of Adipose-Derived Mesenchymal Stem Cells into β-Like Cells both In Vitro and In Vivo

Koichi Kawamoto1#, Shigeharu Yabe2#, Masamitsu Konno3#, Hideshi Ishii3, Naohiro Nishida3, Jun Koseki3, Satsuki Fukuda2, Yoshito Tomimaru1, Naoki Hama1, Hiroshi Wada1, Shogo Kobayashi1, Hidetoshi Eguchi1, Masahiro Tanemura4, Toshinori Ito5, Eun Young Lee6, Eri Mukai6, Takashi Miki6, Yuichiro Doki1, Masaki Mori1, Tatsuo S Hamazaki2, Hiroaki Nagano1* and Hitoshi Okochi2*

1Department of Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

2Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

3Department of Frontier Science for Cancer and Chemotherapy, National Hospital Organization Kure Medical Center, Hiroshima, 737-0023, Japan

4Department of Surgery and Institute for Clinical Research, National Hospital Organization Kure Medical Center, Hiroshima, 737-0023, Japan

5Department of Complementary and Alternative Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

6Department of Medical Physiology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan

#These authors contributed equally to the work

*Corresponding Authors:
Hiroaki Nagano, MD, PhD
Associate Professor, Department of Surgery
Osaka University, Graduate School of Medicine
Suita, Yamadaoka 2-2, Osaka 565-0871, Japan
Tel: +81-(0)6-6879-3251
Fax: +81-(0)6-6879-3259
E-mail: [email protected]
 
Hitoshi Okochi, MD, PhD
Professor, Department of Regenerative Medicine
Research Institute, National Center for Global Health and Medicine
1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan
Tel: +81-(0)3-3202-7181-2727
Fax: +81- 03-3207-1038
E-mail: [email protected]

Received date: July 10, 2014; Accepted date: July 26, 2014; Published date: July 28, 2014

Citation: Kawamoto K, Yabe S, Konno M, Ishii H, Nishida N, et al. (2014) Murine Insulinoma Cell-Conditioned Medium with BETA2/Neurod1 Transduction Efficiently Induces the Differentiation of Adipose-Derived Mesenchymal Stem Cells into β-Like Cells both In Vitro and In Vivo. J Stem Cell Res Ther 4:221. doi:10.4172/2157-7633.1000221

Copyright: © 2014 Kawamoto K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Stem Cell Research & Therapy

Abstract

Background: Mesenchymal stem cells (MSCs), including adipose tissue-derived mesenchymal stem cells (ADSCs), are multipotent and can differentiate into various cell types, including pancreatic β cells. Therefore, ADSCs present a potential cell source for the treatment of type 1 diabetes mellitus (T1DM). However, current in vitro protocols are insufficient to induce fully matured insulin-producing β cells. In this study, we assessed the effectiveness of overexpression of ΒETA2 (NeuroD1), a member of the basic helix–loop–helix transcription factor family, with murine insulinoma cell line-derived conditioned medium (MIN6-CM) to improve the differentiation capacity of ADSCs into insulin-producing cells.
Method: Murine ADSCs were isolated from C57BL/6 mice, transduced with several transcriptional factors (TFs), and stable transfectants were established. MIN6-CM was prepared. Syngeneic recipient mice were rendered diabetic by a single injection of streptozotocin, and differentiated cells were transplanted under the kidney capsule of recipient mice. Next, blood glucose levels were monitored.
Results: CM alone was sufficient to induce insulin mRNA expression in vitro. However, other TFs were not detected. ADSCs cultured with MIN6-CM induced insulin expressions in vitro, but other β cell-related TFs were been detected. However, BETA2 transduction in MIN6-CM resulted in robust expression of multiple β cell phenotypic markers. Moreover, insulin content analysis revealed insulin protein expression in vitro. Furthermore, in vivo transplant studies revealed the effectiveness of the simultaneous use of BETA2 transduction with the CM.
Conclusion: These results suggest that the balance of cytokines and growth factors in addition to gene manipulation would benefit the efficient differentiation of ADSCs into pancreatic β cells. Our technology could provide a path to β cell differentiation and novel cell replacement-based therapies for T1DM.

Keywords

Adipose tissue-derived stem cell (ADSC); BETA2 (NeuroD1); Conditioned medium; Transcription factors; β cells

Abbreviations

ADSC: Adipose Tissue-derived Mesenchymal Stem Cell; CM: Conditioned Medium; iPS: Induced Pluripotent Stem

Introduction

Type 1 diabetes mellitus (T1DM) typically manifests in childhood and has been estimated to account for 5–10% of all diagnosed cases of diabetes. T1DM is characterized by absolute insulin deficiency due to immunological destruction of insulin-secreting pancreatic β cells [1]. The limitation of insulin therapy has been well documented [2]. Therefore, β cell replacement therapy is required for treatment of such patients [3]. Pancreas or islet transplantations are viable treatment options for T1DM [4,5]. However, the side-effects of immunosuppressants cannot be disregarded. Moreover, transplantation on a large scale is limited by the availability of pancreas donors. Thus, β cell regeneration from auto tissue has been proposed as the best strategy to treat diabetes. Almost all β cells are destroyed in patients with established T1DM, stimulating the researcher to produce β cells from other cell types.

Cellular plasticity has been extensively investigated for possible roles in the propagation of pancreatic β cells. Earlier studies have shown that ectopic expression of pancreatic and duodenal homeobox-1 (pdx1) is sufficient to induce expression of insulin in murine liver cells [6]. More recently, since the introduction of induced pluripotent stem cells (iPS), researchers are making a concerted effort again to demonstrate the plasticity of terminally differentiated cells [7]. In the case of pancreatic cell reprogramming, Melton et al demonstrated that acinar cells could be reprogrammed into β cells using a specific combination of three transcription factors (TFs), namely Pdx1, neurogenin 3 (Ngn3), and v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA) [8]. Furthermore, glucagon-producing pancreatic α cells have also been shown to be reprogrammable into β cells [9,10]. These results demonstrated that various cell types present potential cell sources for the treatment of T1DM. However, in vivo reprogramming strategies have several limitations, such as the risk of viral transmission and low reprogramming efficiency for clinical use.

Stem cells, such as embryonic stem cells, as iPS cells, present another attractive source for tissue engineering because they have the capability of self-renewal. Originally, embryonic stem cells held promise as a source of renewable β cells, but their potential has proven more difficult than expected. Alternatively, pancreatic progenitor cells present as possible candidates [11]. Multipotent mesenchymal stem cells (MSCs), which represent a nonhematopoietic cell population, can also differentiate into mesenchymal tissues (i.e., bone, cartilage, or fat) [12]. MSCs were first isolated from bone marrow and later from nonmarrow tissues, including umbilical cord blood and adipose tissue, and are clinically applicable because of easy accessibility and large scale preparation. Thus, adipose tissue-derived mesenchymal stem cells (ADSCs) have been also explored as a possible source of pancreatic β cells.

During vertebrate embryogenesis, the development of pancreas is regulated by the sequential expression of a molecular network of TFs [13]. It is generally accepted that several defined factors are needed in the differentiation of insulin-producing cells [13]. Among them, Pdx1 is thought to be a key transcriptional regulator of endocrine, acinar, and ductal cell development. PDX-1-deficient mice die rapidly after birth due to pancreatic insufficiency [14]. Previously, our research group demonstrated that Pdx1-transfected ADSCs can mature in vivo [15]. The combined expression of Pdx1 and MafA with either Ngn3 or NeuroD are required for both exocrine cell reprogramming and staging differentiation [16]. However, simple transduction of several TFs could not induce β cell maturation. NeuroD1 is a member of the NeuroD family and binds to the E element of the insulin gene [17] to modulate the expression of genes, such as SUR1, which forms K+ channels with Kir6.2 to regulate insulin secretion [18]. The BETA2/NeuroD protein, a class B bHLH TF, has been cloned as a transcriptional activator of the insulin gene [4] and neurogenic factor in Xenopus embryos [2].

Several studies have already found that MSCs have an immunomodulatory effect by both contact-dependent and -independent mechanisms [19-24], and they secrete or release many substances into the surrounding medium. This phenomenon stimulated researchers to use conditioned medium (CM) of MSCs to reduce the toxic effects of ischemia reperfusion injury [25]. We hypothesized that the cocktail of cytokine and growth factors produced by an insulinoma cell line could efficiently induce β cell differentiation into insulin-producing cells because such cells retain the expression of multiple insulin-related genes, including pdx1, paired box protein (pax6), kir6.2, and ins2.

To determine the impact of MIN6-CM on the induction of ADSC differentiation into insulin-producing cells, we cultured ADSCs in MIN6-CM. Here we report that CM per se was sufficient to induce insulin detection by quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR). Next, we assessed whether the combinatorial effect of stable BETA2 transfection with CM would be a useful method for the induction of insulin-producing β cells. Stable expression of BETA2 in ADSCs in MIN6-CM induces a pancreatic phenotype in vitro. The transplantation of these cells into streptozotocin (STZ)-induced diabetic mice results in engraftment of the transplanted BETA2-ADSCs in the pancreas, leading to the amelioration of hyperglycemia.

Materials and Methods

ADSC isolation

Murine ADSCs were isolated from C57BL/6 mice as previously described [26]. In brief, adipose tissue was washed twice with Dulbecco’s phosphate-buffered saline (D-PBS; Invitrogen, Carlsbad, CA, USA) containing 50 U/mL of penicillin and 50 μg/mL of streptomycin (Invitrogen) and were then cut into fine pieces, which were incubated with D-PBS containing 1.0 mg/mL of Clostridium histolyticum collagenase (Sigma-Aldrich, St. Louis, MO, USA) in a 37°C shaking incubator for 1 h. The tissue was filtered through a sterile 70-μm nylon mesh and resuspended in Dulbecco’s modified Eagle’s medium (DMEM; (Nacalai Tesque, Kyoto, Japan) supplemented with 10% fetal bovine serum (FBS; HyClone; Thermo Scientific, Waltham, MA, USA), penicillin, and streptomycin.

Preparation of CM

To generate CM, a murine insulinoma cell line, MIN6 cells were allowed to grow to 50% confluence with standard DMEM with 10% FBS, PSM, sodium pyruvate, and 2-mercaptoethanol (Nacalai Tesque, Inc., Kyoto, Japan) in 150-mm dishes (Figure 1A). Next, DMEM was replaced with a new media on day 2. After a 48-h culture period, the medium was collected (MIN6-CM#1) and replaced to a fresh medium. Then, CMs were collected every 48-h incubation. CM#1, CM#2, and CM#3 were pooled and filtered using a bottle-top filter (Corning Incorporated, Corning, NY, USA) to remove cells and debris. CM samples were frozen at −20°C for later use. MIAPaCa-2 and PANC- 1 cell lines were grown in complete medium supplemented with 10% FBS to produce pancreatic cancer cell line-derived CM. MIAPaCa-2- derived CM (MIAPaCa-CM) and PANC-1-derived CM (PANC-CM) were also prepared using the same protocol.

stem-cell-research-therapy-adipose-derived-mesenchymal

Figure 1: Schematic representation of this study. (A) Preparation of conditioned medium (CM). (B) adipose-derived mesenchymal stem cells (ADSCs) or genemanipulated ADSCs were cultured in murine insulinoma cell line-derived CM (MIN6-CM) for 3 weeks and then divided into two groups. (C) Morphological change of ADSCs and subclones cultured with MIN6 conditioned medium. (D) ADSC with PANC-CM. (E) Polymerase chain reaction (PCR) analysis of Ins2.

Quantitative real-time reverse transcription polymerase chain reaction

For mRNA detection, total RNA from both pre- and post-treated cells were extracted in TRIzol Reagent (Invitrogen), and cDNA was amplified by qRT-PCR. β-actin was used as an internal control for normalization. All reactions were performed along with negative (water) and positive (pancreatic cells) controls.

Immunostaining

For immunocytochemical analysis, cells were plated in a 60-mm dish, washed twice with D-PBS, and fixed with 4% paraformaldehyde for 20 min at room temperature. Then, the dishes were washed three times with D-PBS and treated with 0.5% Triton X-100 in PBS for 15 min. The cells were treated with 3% BSA–PBS for 60 min and stained with C-peptide (1:400 dilution; Cell Signaling Technology #4593, Danvers, MA, USA) for 16 h at 4°C, and then treated with a second antibody (AlexaFluor 647) for 60 min at room temperature. Nuclei were counter-stained with 4′,6-diamidino-2-phenylindole (DAPI).

Insulin content measurements and glucose-stimulated insulin release (GSIS)

For insulin content and GSIS analysis, cells were seeded in a 6-well plate, cultured for 16 h, and then placed for 30 min in medium containing 3 mM glucose (Lo glucose), which was then replaced with a media containing the various constituents indicated and incubated again for an additional 60 min. The supernatant was frozen for later use. The cells were then lysed with acid ethanol at 4°C for 16 h. Cell lysates were collected and stored at -80°C. Insulin levels were then determined in both GSIS and intracellular contents using the ultra-sensitive “PLUS” mouse insulin ELISA kit (Morinaga Institute of Biological Science, Inc., Yokohama, Japan). TMB (3,3′,5,5′-tetramethylbenzidine) solution was added to each well, and the plates were then incubated for 40 min, until the reaction was terminated by the addition of an equal volume of stopping solution; optical density was determined at 450/630 nm (PerkinElmer, Waltham, MA, USA).

FACS analysis

Cells were treated with Accutase reagent (EMD Millipore, Billerica, MA, USA) to dissociate the cells, which were then resuspended in staining media [DPBS supplemented with FBS (1%) and EDTA (2 mM)]. Next, the cells were stained with fluorescein isothiocyanateconjugated anti-mouse CD71 (Clone C2; BD Pharmingen, Franklin Lakes, NJ, USA), phycoerythrin-conjugated anti-mouse CD31 (eBioscience, San Diego, CA, USA), APC-anti mouse CD140a (Clone APA5; BioLegend, San Diego, CA, USA), eFluor450 anti-mouse CD45, and allophycocyanin-conjugated anti-mouse CD90.2 for 30 min on ice.

Retroviral preparation

Pdx1 cDNA was obtained as previously described [15]. The open reading frame of the human Pdx1 gene was integrated into the retrovirus vector pMSCV-puro. To prepare the retroviruses, PT67 cells were cultured in DMEM supplemented with 10% FBS and PSM with puromycin. Fugene 6 transfection reagent (Promega, Madison, WI, USA) was diluted with 500 μL of DMEM and incubated for 5 min at room temperature. Plasmid DNA (2.5 μg) was added to the mixture, which was incubated for an additional 15 min at room temperature. Then, the culture media was replaced with fresh DMEM supplemented 10% FBS and the DNA/Fugene 6 mixture was added dropwise onto the HEK-293Ta cells. The medium was replaced after 24 h. After an additional 48 h, virus-containing supernatants, derived from the HEK- 293Ta cultures, were filtered through a 0.22-μL cellulose–acetate filter and used.

Sphere formation

To assess the impact of TFs and CMs for the induction or maintenance of β-like cells, the sphere formation protocol was employed. In brief, control or TF-transduced ADSCs were placed in an ultra-low attachment 96-well round bottom plate with hydrogel (Costar 7007) at a density of 1000 cells/well. Colonies were picked up on day 2 and plated on either gelatin-coated or uncoated Petri dishes (Sansyo Co., Ltd., Tokyo, Japan).

Transplantation to diabetic mice

Eight–12-week-old female B6 mice were housed in an airconditioned environment under a 12-h light–dark cycle. Freshly dissolved STZ (Nacalai Tesque) was used to make a concentration of 10 mg/mL stock solution. Then, the recipient mice were rendered diabetic by a single intraperitoneal injection of 200 mg/kg STZ prior to transplantation. Next, blood glucose levels were monitored every other day and confirmed for hyperglycemia (400 mg/dL). The cells were transplanted under the left kidney capsular space of the recipient diabetic mice using a Hamilton syringe with a 26-gauge needle. Then, the blood glucose levels were monitored every other day using a commercial blood glucose meter.

Statistical analyses

Data are presented as means ± standard errors of the mean of independent experiments. Statistical testing was performed using the Student’s t-test to detect differences between groups. In cases of multiple groups testing, analysis of variance was conducted followed by a posteriori t-test. Differences were considered statistically significant at p<0.05 (*) and <0.001 (**).

Results

CM with transcription factor ΒETA2-induced efficient differentiation of ADSCs into multiple TF-positive β-like cells

Figures 1A and 1B describe the experimental protocol used in this study. MIN6-CM was prepared as described in the Materials and Methods section. First, we evaluated the morphological changes of ADSCs and their subclones cultured with MIN6-CM. As shown in Figure 1C, the morphological differences were minimal. However, there was a trend of round morphology among the cultured BETA2- ADSCs. When ADSCs were cultured with CM from the human pancreatic carcinoma cell line MIAPaCa-CM, ADSCs displayed massive apoptosis within 9 days (Data not shown). Next, we assessed the impact of PANC-CM. In contrast to MIAPaCa-CM, ADSCs can grow with PANC-CM with both epithelial-like and neuron-like colonies (Figure 1D). However, ins2 message was not detected in PANC-CM-ADSC compared to MIN6 (Figure 1E). Next, we assessed the effect of MIN6-CM on ADSC. Surprisingly, CM culture for 1 week was sufficient for insulin detection by qRT-PCR (Figure 2A). These results suggest that MIN6-CM would be useful for induction of β cell differentiation. However, other TFs, such as pax6 and kir6.2, were not detected in this group during the overall 5-week culture period. Next, we assessed the differentiation efficiencies of MIN6-CM in combination with several TFs. As presented in Figure 2A, Pdx1-ADSC with CM was not effective to induce multiple TFs. However, ΒETA2-ADSCs with MIN6-CM resulted in efficient differentiation into insulin-producing cells. As early as culture day 3, both pax6 and kir6.2 were detected, and their expressions were retained. These results clearly demonstrate that BETA2 would be the best partner for CM-mediated differentiation. We further confirmed the effectiveness of this combination by qRT-PCR. Pdx-1 overexpression with CM resulted in a synergistic upregulation of insulin messaging (Figure 2B). Furthermore, BETA2-ADSC with CM resulted in more effective induced insulin expression.

stem-cell-research-therapy-cell-line-derived

Figure 2: (A) BETA2- adipose-derived mesenchymal stem cells (ADSCs) with murine insulinoma cell line-derived conditioned medium (MIN6-CM) induced ins2, Pax6, and Kir6.2 expression. (B) Quantitative real-time reverse transcriptase PCR analysis. (C) The effect of feeder. (D) Effect of passage to ADSC culture.

We next used nicotinamide for further maturation of β-like cells. As shown in Figure 2A, nicotinamide did not further enhance mRNA levels of Pax6, Kir6.2, or Ins2. Thus, nicotinamide addition was not very effective for further maturation of β-like cells. Then, we selected nicotinamide-free culture media for further experiments. For Pdx1-ADSC without MIN6-CM, insulin expression was not detected (control group), which was in accordance with the results of our previous report [12]. Next, we evaluated the MEF-feeder effect. As shown in Figure 2C, the MEF feeder impaired differentiation of β-like cells. These results suggest that MEF seemed to not partner well with MIN6-CM. An interesting observation was that no passaged group had a better outcome than the standard passaged group as it showed more intense insulin banding (Figure 2D). Furthermore, endogenous BETA2-expression was observed in the passaged group. These results demonstrated that the usual passage protocol was better for β cell maturation.

Insulin protein expression of MIN6-CM-cultured ADSCs

Next, we detected insulin protein expression. First, we employed C-peptide immunocytochemistry to support the notion that these β-like cells produced functional insulin [27]. Immunocytochemical analysis showed that C-peptide was undetectable (Figure 3A). Neither Pdx-ADSC nor PN-ADSC with MIN6-CM expressed detectable insulin levels by immunocytochemical analysis (Data not shown). However, there were clearly significant differences in insulin content between the controls parental ADSCs and MIN6-CM-cultured BETA2-ADSCs (Figure 3B) under both low and high glucose conditions (p<0.05). Next, we measured glucose-dependent insulin release by ADSCs in vitro. As shown in Figure 3C, MIN6-CM-cultured BETA2-ADSCs did not release insulin in response to a step-wise increase of glucose to 25 mM (high glucose). These results showed that insulin was detectable by insulin content, but these cells did not release insulin in response to physiologically relevant glucose concentrations in vitro.

stem-cell-research-therapy-BETA2-adipose-derived

Figure 3: In vitro analysis of BETA2- adipose-derived mesenchymal stem cells (ADSCs) cultured with murine insulinoma cell line-derived conditioned medium (MIN6- CM). (A) Immunocytochemical analysis of C-peptide. (B) Insulin content analysis. (C) Glucose-stimulated insulin secretion. (D) Surface marker analysis.

Next, we analyzed the expression of MSC markers, including CD71, CD90.2, CD140a, and Sca-1. As shown in Figure 3D, the expression level of CD71, CD90.2, and CD140a were downregulated, whereas that of Sca-1 was upregulated. These results suggest that the MIN6-CM culture induced downregulation of mesenchymal markers. In contrast, Sca-1 seemed to be a maturation marker in our protocol.

Transplantation to in vivo STZ-diabetic mice

We investigated whether the BETA2-ADSCs with CM exhibited relevant in vivo function for the treatment of diabetes. Thus, we employed a STZ-induced diabetic mouse model through the administration of 200 mg/kg STZ into the peritoneum of 8–12-week-old female B6 (Figure 4A). We attempted to determine whether BETA2-ADSCs with CM were capable of controlling blood glucose levels in diabetic mice. First, we assessed the diabetogenic effect of STZ. As shown in Figure 4C, STZtreated mice showed elevated blood glucose levels. Next, we evaluated whether the transplanted cells could control STZ-induced diabetes of recipient mice. As shown in Figure 4C, the recipient mice showed better blood glucose maintenance. Moreover, the beneficial effect of CM-cultured BETA2-ADSC transplantation also demonstrated a trend of better survival compared with the control group. There was no overt tumor in sacrifice mice. Thus, these transplanted ADSCs apparently did not participate in tumor formation.

stem-cell-research-therapy-streptozotocin-treated-diabetic

Figure 4: Blood glucose levels and survival of streptozotocin-treated diabetic mice. (A) A schematic representation of in vivo transplantation. (B) Representative cell transplant under the left kidney capsule. (C) Blood glucose levels of STZ-treated mice after cell transplantation. Comparison of blood glucose levels in ADSCtransplanted mice (blue, n = 4) and BETA2-ADSC-CM-transplanted mice (red, n = 4). Data are presented as mean ± SEM.

Sphere formation analysis

Next, we assessed the impact of TFs and CMs to induce or maintain β-like cells. As shown in Figure 5A, ADSCs formed spheres when transferred to an ultra-low attachment 96-well round plate. However, hand-picked spheres were attached to the dish when plated in either gelatin-coated dishes (adhesive condition) or standard non-coated Petri dishes (non-adhesive condition). BETA2-ADSCs with MINCM were more adhesive compared with PDX-ADSCs with MIN-CM (Figure 5B). These results suggest the importance of BETA2 for sphere expansion. Unfortunately, C-peptide protein was not detected even with sphere formation (Figure 5C).

stem-cell-research-therapy-Sphere-formation-analysis

Figure 5: Sphere formation assay. (A) Sphere formation analysis on day 3. (B) Sphere formation of day 7. (C) C-peptide immunocytochemistry of sphere analysis.

Discussion

Here we report a novel combination of two techniques (BETA2 transduction and MIN6-CM culture) with a great potential to refine the β cell differentiation protocol. The balance of cytokines and growth factors in CM plays important roles in both efficient differentiation and functional maintenance of certain cell types. In this study, we found that ADSCs could express detectable insulin levels by qRT-PCR using parental MIN6-CM culture in vitro. Compared to our previous experience with Pdx1-ADSCs without CM, CM treatment only was enough to facilitate insulin expression in vitro. These results suggest that CM would be a useful induction agent for β cell differentiation. Furthermore, the forced expression of the ΒETA2 gene in murine ADSCs in the presence of MIN6-CM resulted in robust differentiation of these cells into insulin-producing cells. Using this novel technology, multiple TFs, including pax6 and kir6.2, were detected as early as culture day 3. Moreover, insulin expression of BETA2-ADSC with MIN6-CM was confirmed by insulin content analysis. Furthermore, these cells could control hyperglycemia of STZ-induced diabetic mice. These results clearly demonstrated that this combination is a promising candidate for refinement of current β cell differentiation protocols. Of note, these effects of CM were observed only in the parenteral MIN6 cell line. When the subclones MIN6-m9 and MIN6-m14 were used, this phenomenon was not observed (data not shown). These results suggest that the selection of effective CM-producing cell offers potentially important advancements in β cell replacement therapy.

In previous studies, we reported that Pdx1-transfected ADSCs with standard bovine serum-based medium lacked expression of pancreatic marker genes, including the two non-allelic insulin genes insulin 1 and insulin 2 [15]. These results suggested that the transduction of a single TF would be insufficient for in vitro detection of the insulin gene. However, Pdx1-ADSCs can produce insulin after in vivo maturation for 30 days when administered systemically [15]. These results suggest that in vivo maturation may contribute for further β cell maturation, at least, in part, in our previous model. In the present study, we confirmed that Pdx1-ADSCs and BETA2-ADSCs lack ins2 expression (Figure 2). Also, the same can be said about the results of the present study from the point of the importance of in vivo maturation because BETA2- ADSC with MIN6-CM resulting in insulin protein was detected only by the insulin content assay. It is noteworthy that there was a trend in the BETA2-ADSCs with CM in lower glucose levels compared with Pdx1- ADSCs (historical control). In our previous study, we used intravenous tail vein cell transfer. In the present study, we employed subrenal capsular transplant, which is a more efficient site for transplantation of β-like cells. Although a proper mechanism for the effectiveness of MIN6-CM has not been clarified at present, the balance of cytokine and growth factor content may be critical for efficient β cell differentiation. As expected, BETA2-ADSCs with MIN6-CM lost expression of the mesenchymal markers CD71, CD90, and CD140a. Recently, we reported that CD90-Hi ADSCs were reprogrammed more efficiently compared with CD90-Lo ADSCs [28]. The importance of Sca-1 has already been suggested in ductal progenitor theory [29]. In this study, Sca-1 expression was upregulated, perhaps because Sca-1 is a marker of stem and pancreatic progenitor cells. Therefore, the upregulation of Sca-1 may reflect the upregulation of progenitor properties.

A possible limitation of this study is that normoglycemia was not achieved in this model. The importance of MafA for pancreatic development is well recognized. Therefore, our next project is to add the factor of MafA overexpression to this combination. Another limitation of this study was the use of viral vector gene transfer. However, this and previous studies have already demonstrated that the viral-free method is clinically relevant to stem cell therapy [30-32]. A previous report also suggested that BETA2 can be transduced by non-viral methods using the protein transduction domain [33]. Thus, BETA2 overexpression using a non-viral method would present a powerful option for future clinical use. Moreover, chemicals that induce latestage β-cell differentiation have been reported [34]. Therefore, these technologies, along with our method, will further advance functional β-cell induction technology.

In summary, we successfully treated STZ-induced diabetic mice by ADSC transplantation, suggesting that this technology may open new avenues toward clinical applications of ADSCs for T1DM treatment.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 20th Global Congress on Biotechnology March 5-7, 2018 London, UK
    March 5-7, 2018 London, UK
  • 7th International Conference and Exhibition on Cell and Gene Therapy March 15-16, 2018 London,UK
    March 15-16, 2018 London, UK
  • 10th World Congress and Expo on Cell & Stem Cell Research March 19-21, 2018 New York, USA
    March 19-21, 2018 New York, USA
  • 4th World Congress on Human Genetics and Genetic Diseases April 19-20, 2018 Dubai, UAE
    April 19-20, 2018 Dubai, UAE
  • 3rd International Conference on Molecular Medicine and Diagnostics April 19-20, 2018 Dubai,UAE
    April 19-20, 2018 Dubai, UAE
  • 11th World Congress on Cell & Tissue Science May 09-10, 2018 Tokyo, Japan
    July 19-20, 2018 Dubai, UAE
  • 11th World Congress on Cell & Tissue Science May 09-10, 2018 Tokyo, Japan
    May 09-10, 2018 Tokyo, Japan
  • 6th International Conference on Integrative Biology May 21-23, 2018 Barcelona, Spain
    May 21-23, 2018 Barcelona, Spain
  • 10th International Conference on Genomics and Molecular Biology May 21-23, 2018 Barcelona, Spain
    May 21-23, 2018 Barcelona, Spain
  • 12th Annual Conference on Stem Cell and Regenerative Medicine June 04-06, 2018 Prague, Czech Republic
    June 04-06, 2018 Prague, Czech Republic
  • 4th International Conference on Bioscience July 2-3, 2018 Vienna, Austria
    July 2-3, 2018 Vienna, Austria
  • 22nd World Congress on Biotechnology July 10-11, 2018 Bangkok, Thailand
    April 16-18, 2018 Amsterdam, Netherlands
  • 9th International Conference on Tissue Science and Regenerative Medicine July 13-14, 2018 Sydney, Australia
    April 23-24, 2018 Las Vegas, USA
  • 10th Annual Conference on Stem Cell and Regenerative Medicine August 13-14, 2018 London, UK
    August 13-14, 2018 London, UK
  • World Congress on Stem Cell Biology and Biobanking September 3-4, 2018 Tokyo, Japan
    September 3-4, 2018 Tokyo, Japan
  • 2nd Annual summit on Cell Metabolism and Cytopathology September 19 - 20, 2018 Philadelphia, Pennsylvania, USA
    September 19 - 20, 2018 Philadelphia, USA
  • 2nd Annual summit on Cell Signaling and Cancer Therapy September 19 - 20, 2018 Philadelphia, Pennsylvania, USA
    September 19 - 20, 2018 Philadelphia, USA
  • 6th Annual Congress on Biology and Medicine of Molecules September 20-21,2018 Kuala Lumpur, Malaysia
    September 20-21,2018 Kualalumpur, Malaysia
  • 5th International Conference on Human Genetics and Genetic Disorders September 21-22,2018 Philadelphia, Pennsylvania, USA
    September 21-22,2018 Philadelphia, USA
  • 11th International Conference on Genomics and Pharmacogenomics September 21-22, 2018 Philadelphia, Pennsylvania, USA
    September 21-22, 2018 Philadelphia, USA
  • 5th World Congress on HUMAN GENETICS SEPTEMBER 24-25, 2018 BERLIN, GERMANY
    SEPTEMBER 24-25, 2018 Berlin, Germany
  • 21st Euro Biotechnology Congress October 11-12, 2018 Moscow, Russia
    October 11-12, 2018 Moscow, Russia
  • 11th International Conference on Tissue Engineering & Regenerative Medicine October 18-20, 2018 Rome, Italy
    October 18-20, 2018 Rome, Italy
  • 24th Biotechnology Congress: Research & Innovations October 24-25, 2018 Boston, USA
    October 24-25, 2018 Boston, USA
  • International Conference on Human Genome Meeting October 25-26, 2018 Istanbul, Turkey
    October 25-26, 2018 Istanbul, Turkey
  • International Congress & Expo on Genomics and Bioinformatics November 2-3, 2018 Columbus, Ohio, USA
    November 2-3, 2018 Columbus, USA
  • 12th International Conference & Exhibition on Tissue Preservation and Biobanking November 9-10, 2018 Atlanta, Georgia, USA
    November 9-10, 2018 Atlanta, USA
  • 2nd Annual Summit on Cell Therapy and Stem Cell Research November 9-10, 2018 Atlanta, Georgia, USA
    November 9-10, 2018 Atlanta, USA

Article Usage

  • Total views: 11772
  • [From(publication date):
    August-2014 - Dec 14, 2017]
  • Breakdown by view type
  • HTML page views : 7977
  • PDF downloads : 3795
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]ine.com

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version